Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

The effects of sorafenib – an oral multikinase inhibitor targeting the tumour and tumour vasculature – were evaluated in patients with advanced melanoma enrolled in a large multidisease Phase II randomised discontinuation trial (RDT). Enrolled patients received a 12-week run-in of sorafenib 400 mg t...

Descripción completa

Detalles Bibliográficos
Autores principales: Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, Gibbens, I, Hackett, S, James, M, Schuchter, L M, Nathanson, K L, Xia, C, Simantov, R, Schwartz, B, Poulin-Costello, M, O'Dwyer, P J, Ratain, M J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360687/
https://www.ncbi.nlm.nih.gov/pubmed/16880785
http://dx.doi.org/10.1038/sj.bjc.6603291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360687/
https://www.ncbi.nlm.nih.gov/pubmed/16880785
http://dx.doi.org/10.1038/sj.bjc.6603291

Ejemplares similares